Literature DB >> 16948991

[Bacterial etiology of chronic bronchitis exacerbations treated by primary care physicians].

Carles Llor1, Josep Maria Cots, Amadeo Herreras.   

Abstract

OBJECTIVE: Few studies have been carried out to determine the prevalence of microorganisms causing exacerbations of chronic bronchitis in the community setting. The aim of the present study was to determine the bacterial etiology of chronic bronchitis exacerbations in patients not requiring hospitalization. PATIENTS AND METHODS: This observational, cross-sectional, multicenter study was carried out at the primary care level during 2 weeks (in November 2001 and January 2002). All laboratory work was carried out at a single center. We studied 1,947 patients with mild-moderate exacerbations treated by 650 primary care physicians. All the sputum samples received for centralized processing were subject to Gram staining, microscopic examination, and bacterial culture.
RESULTS: Out of 1,537 cultures of sputum samples collected, 498 had good cell quality for microscopic examination (32.4%). Of the 498 good quality samples analyzed, 246 (49.4%) were positive and 468 isolates were obtained. The most commonly isolated germ was Streptococcus pneumoniae (163 cases, 34.8%), followed by Moraxella catarrhalis (112, 23.9%), and Haemophilus influenzae (59, 12.6%). In 1.2% of the S. pneumoniae isolates resistance was found to amoxicillin; resistance to macrolides was found in 34.3%. The antibiotics most commonly prescribed, however, were macrolides (38.3% of the prescriptions).
CONCLUSIONS: S. pneumoniae was the microorganism most frequently isolated in cases of chronic bronchitis exacerbation treatable in this outpatient setting.

Entities:  

Mesh:

Year:  2006        PMID: 16948991     DOI: 10.1016/s1579-2129(06)60552-1

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  5 in total

Review 1.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

2.  Evaluation of a rapid immunochromatographic ODK0501 assay for detecting Streptococcus pneumoniae antigen in sputum samples from patients with lower respiratory tract infection.

Authors:  Koichi Izumikawa; Suguru Akamatsu; Akiko Kageyama; Kiyomi Okada; Yukumasa Kazuyama; Noboru Takayanagi; Shigeki Nakamura; Yuichi Inoue; Yasuhito Higashiyama; Kiyoyasu Fukushima; Tadashi Ishida; Toyomitsu Sawai; Kunihiko Yoshimura; Chikara Nakahama; Mitsuhide Ohmichi; Tomoyuki Kakugawa; Yasuhiko Nishioka; Nobuki Aoki; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Shigeru Kohno
Journal:  Clin Vaccine Immunol       Date:  2009-03-04

3.  Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease.

Authors:  Christopher Jd Threapleton; Sadia Janjua; Rebecca Fortescue; Emma H Baker
Journal:  Cochrane Database Syst Rev       Date:  2019-05-24

4.  [Antibiotic susceptibility of Staphylococcus aureus and Streptococcus pneumoniae in healthy carrier individuals in primary care in Barcelona area].

Authors:  Carles Llor; Albert Boada; Mariona Pons-Vigués; Elisabet Grenzner; Rosa Juvé; Jesús Almeda
Journal:  Aten Primaria       Date:  2017-04-14       Impact factor: 1.137

5.  Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care.

Authors:  Carl Llor; Silvia Hernández; Anna Ribas; Carmen Alvarez; Josep Maria Cots; Carolina Bayona; Isabel González; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.